Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

Expert Opinion on Investigational Drugs

Volumn 20, Issue 2, 2011, Pages 287-295

  Prebet, Thomas ^a,b,c   Vey, Norbert ^a,b,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

epigenetic; HDAC; leukemia; myelodysplasia

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; AZACITIDINE; BELINOSTAT; CLOFARABINE; CYTARABINE; DACINOSTAT; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MOCETINOSTAT; PANOBINOSTAT; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; ROMIDEPSIN; SORAFENIB; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ADVANCED LEUKEMIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CONSTIPATION; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG ACETYLATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; IC 50; LEUKEMIA; LEUKOPENIA; LIVER FUNCTION TEST; LIVER METABOLISM; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NAUSEA; NEUROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; PROTEINURIA; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT REDUCTION; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES;

EID: 79951874108     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.542750     Document Type: Article

References (63)

1. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009;113(6):6296-303.
2. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74.
3. Estey E. Acute myeloid leukemia and myel (Pubitemid 46854425)
4. Estey E. New drugs in acute myeloid leukemia. Semin Oncol 2008;35(4):439-48.
5. Gore SD. New agents for the treatment of AML recent study findings. Clin Adv Hematol Oncol 2008;6(11):6-8.
6. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59.
7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349(21):2042-54. (Pubitemid 37448928)
8. Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007;13(1):23-9.
9. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113(6):1315-25.
10. Bullinger L, Ehrich M, Dohner K, et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010;115(3):636-42.
11. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20(10):2429-40. (Pubitemid 34525728)
12. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10(3):223-32.
13. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106(8):1794-803.
14. Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007;110(5):943-54. (Pubitemid 47312858)
15. Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106(1):112-19. (Pubitemid 43032555)
16. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109(7):2781-90. (Pubitemid 46482071)
17. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12(15):4628-35. (Pubitemid 44297814)
18. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293(5532):1074-80. (Pubitemid 32758077)
19. Linggi BE, Brandt SJ, Sun ZW, Hiebert SW. Translating the histone code into leukemia. J Cell Biochem 2005;96(5):938-50. (Pubitemid 41688720)
20. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009;15(12):3947-57.
21. Oki Y, Issa JP. Epigenetic mechanisms in AML - a target for therapy. Cancer Treat Res 2009;145:19-40.
22. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97(18):10014-19.
23. Vrana JA, Decker RH, Johnson CR, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999;18(50):7016-25. (Pubitemid 30028872)
24. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98(19):10833-8. (Pubitemid 32878706)
25. Takahashi S, Harigae H, Kameoka J, et al. AML1B transcriptional repressor function is impaired by the Flt3-internal tandem duplication. Br J Haematol 2005;130(3):428-36. (Pubitemid 43899593)
26. Miller CP, Rudra S, Keating MJ, et al. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009;113(18):4289-99.
27. Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009;9(6):761-76.
28. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108(4):1174-82. (Pubitemid 44232012)
29. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21(1):103-7. (Pubitemid 29036293)
30. Fiskus W, Rao R, Fernandez P, et al. Molecular and biologic characterization and drug-sensitivity of pan histone deacetylase inhibitor resistant acute myeloid leukemia cells. Blood 2008;112(7):2896-905.
31. Park MA, Zhang G, Martin AP, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008;7(10):1648-62.
32. Dedes KJ, Dedes I, Imesch P, et al. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 2009;20(5):321-33.
33. Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007;13(24):7237-42.
34. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9. (Pubitemid 46053039)
35. Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008;49(3):502-7. (Pubitemid 351298334)
36. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998;95(6):3003-7. (Pubitemid 28135844)
37. Salmi-Smail C, Fabre A, Dequiedt F, et al. Modified CAP group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. J Med Chem 2010;53(8):3038-47.
38. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24(1):166-73. (Pubitemid 46630509)
39. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923-31. (Pubitemid 46218695)
40. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060-6. (Pubitemid 351213383)
41. Rubin EH, Agrawal NG, Friedman EJ, et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006;12(23):7039-45. (Pubitemid 44974501)
42. Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94(10):1375-82.
43. Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control 2008;15(Suppl):40-9.
44. Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110(1):267-77. (Pubitemid 47026844)
45. Mahalingam D, Medina EC, Esquivel JA II, et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 2010;16(1):141-53.
46. Urbich C, Rossig L, Kaluza D, et al. HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood 2009;113(22):5669-79.
47. Kouraklis G. HDAC inhibitors in leukemia: current status and perspectives. Leuk Res 2009;33(2):207-8.
48. Garcia-Manero G, Tambaro F, Nebiyou Bekele B, et al. Phase II study of vorinostat in combination with idarubicin (Ida) and cytarabine (ara-C) as front line therapy in acute myelogenous leukemia (AML) or higher risk myelodysplastic syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 2009;114(22):1055.
49. Kadia TM, Yang H, Ferrajoli A, et al. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 2010;150(1):72-82.
50. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66(12):6361-9.
51. Raffoux E, delabarthe A, Cras A, et al. Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: results of the French VIVEDEP Phase II Study. Oncotarget 2010;1(5):34-42.
52. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110(7):2302-8. (Pubitemid 47523148)
53. Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenyl butyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 2005;23(17):3906-11. (Pubitemid 46218693)
54. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium. J Clin Oncol 2008;26(Suppl):Abstract 7000.
55. Kirschbaum M, Gojo I, Goldberg SL, et al. Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): a phase I, dose-escalation study. Blood (ASH Annual Meeting Abstracts) 2009;114(22):2089.
56. Bruserud O, Stapnes C, Ersvaer E, et al. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 2007;8(6):388-400. (Pubitemid 350268198)
57. Yaswen P. HDAC inhibitors conquer Polycomb proteins. Cell Cycle 2010;9(14):2705.
58. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15(16):5250-7.
59. Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112(4):981-9.
60. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105(3):959-67. (Pubitemid 40170861)
61. Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2008;112(11):958.
62. Prebet T, Gore SD, Sun Z, et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasiarelated changes: results of the US Leukemia Intergroup Trial E1905. Blood (ASH Annual Meeting Abstracts) 2010;116(21);4013.
63. Garcia-Manero G, Yang AS, Klimek V, et al. Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). J Clin Oncol 2007;25(18S, June 20):7062